Metagenomi, Inc. Common Stock (MGX)
Metagenomi, Inc. Common Stock operates in the Biotechnology industry of the Healthcare sector, headquartered in Emeryville, CA, US. The stock last traded at $1.21, down 1.63% on the session, giving a market capitalisation of $45.6M. On trailing twelve-month figures it carries a trailing P/E of -0.49, a net margin of -689.2%. Its beta of 0.67 implies it has historically moved less than the broad market.
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
Metagenomi, Inc. Common Stock is most often compared with the following Healthcare names: